Overview

Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors

Status:
Recruiting
Trial end date:
2021-10-17
Target enrollment:
Participant gender:
Summary
Clinical study of HEC68498 in patients with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity of HEC68498 in patients with advanced refractory solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
Sunshine Lake Pharma Co., Ltd.